Uploaded image for project: 'eCQM Issue Tracker'
  1. eCQM Issue Tracker
  2. CQM-5805

Enoxaparin 40mg/0.4mL

XMLWordPrintable

    • Icon: EH/CAH eCQMs - Eligible Hospitals/Critical Access Hospitals EH/CAH eCQMs - Eligible Hospitals/Critical Access Hospitals
    • Resolution: Answered
    • Icon: Moderate Moderate
    • None
    • None
    • Hide
      ​Two lower dose formulations of enoxaparin were added starting in reporting year 2022:
            854228 0.3 ML enoxaparin sodium 100 MG/ML Prefilled Syringe
            854235 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe
      While Enoxaparin 30 mg and 40 mg is not a therapeutic dose they can be used to administer a therapeutic dose to meet clinical intent. Therefore, we added all applicable RXNORM codes including Enoxaparin 30 mg and 40 mg into the “Anticoagulent Therapy” (oid: 2.16.840.1.113883.3.117.1.7.1.200) value set for the 2022 reporting year onward.
      Show
      ​Two lower dose formulations of enoxaparin were added starting in reporting year 2022:       854228 0.3 ML enoxaparin sodium 100 MG/ML Prefilled Syringe       854235 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe While Enoxaparin 30 mg and 40 mg is not a therapeutic dose they can be used to administer a therapeutic dose to meet clinical intent. Therefore, we added all applicable RXNORM codes including Enoxaparin 30 mg and 40 mg into the “Anticoagulent Therapy” (oid: 2.16.840.1.113883.3.117.1.7.1.200) value set for the 2022 reporting year onward.
    • CMS0071v11
    • Stroke 3

      I noticed a huge discrepancy in our STK3 rates between eCQM and GWTG. After review, I found that our ischemic patients with Afib were discharged on Enoxaparin 40mg/0.4ml. After looking at the VSAC values, this dosage of the prefilled syringe is not included. Please advise.

      Thank you so much.

            JLeflore Joelencia Leflore
            vec9020 Verlin Guanga (Inactive)
            Votes:
            0 Vote for this issue
            Watchers:
            2 Start watching this issue

              Created:
              Updated:
              Resolved:
              Solution Posted On: